Cover Image
市場調查報告書

InSite Vision Incorporated:產品平台分析

InSite Vision Incorporated - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224681
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
InSite Vision Incorporated:產品平台分析 InSite Vision Incorporated - Product Pipeline Review - 2015
出版日期: 2015年06月17日 內容資訊: 英文 40 Pages
簡介

InSite Vision Incorporated是眼科治療藥的開發企業。

本報告提供InSite Vision Incorporated的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

InSite Vision Incorporated的基本資料

InSite Vision Incorporated概要

  • 主要資訊
  • 企業資料

InSite Vision Incorporated:R&D概要

  • 主要的治療範圍

InSite Vision Incorporated:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

InSite Vision Incorporated:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

InSite Vision Incorporated:藥物簡介

  • (azithromycin + dexamethasone)
  • dexamethasone acetate
  • ISV-303
  • ISV-101
  • bimatoprost
  • ISV-405
  • ketorolac tromethamine
  • tetracycline

InSite Vision Incorporated:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

InSite Vision Incorporated:最近的開發平台趨勢

InSite Vision Incorporated:暫停中的計劃

InSite Vision Incorporated:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • ISV-208

InSite Vision Incorporated:企業發表

InSite Vision Incorporated:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07184CDB

Summary

Global Markets Direct's, 'InSite Vision Incorporated - Product Pipeline Review - 2015', provides an overview of the InSite Vision Incorporated's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of InSite Vision Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of InSite Vision Incorporated including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of InSite Vision Incorporated's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the InSite Vision Incorporated's pipeline products

Reasons to buy

  • Evaluate InSite Vision Incorporated's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of InSite Vision Incorporated in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the InSite Vision Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of InSite Vision Incorporated and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of InSite Vision Incorporated
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of InSite Vision Incorporated and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • InSite Vision Incorporated Snapshot
    • InSite Vision Incorporated Overview
    • Key Information
    • Key Facts
  • InSite Vision Incorporated - Research and Development Overview
    • Key Therapeutic Areas
  • InSite Vision Incorporated - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • InSite Vision Incorporated - Pipeline Products Glance
    • InSite Vision Incorporated - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • InSite Vision Incorporated - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • InSite Vision Incorporated - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • InSite Vision Incorporated - Drug Profiles
    • dexamethasone acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISV-303
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISV-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bimatoprost
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ISV-405
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ketorolac tromethamine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tetracycline
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (bromfenac sodium + dexamethasone acetate)
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • InSite Vision Incorporated - Pipeline Analysis
    • InSite Vision Incorporated - Pipeline Products by Target
    • InSite Vision Incorporated - Pipeline Products by Route of Administration
    • InSite Vision Incorporated - Pipeline Products by Molecule Type
    • InSite Vision Incorporated - Pipeline Products by Mechanism of Action
  • InSite Vision Incorporated - Recent Pipeline Updates
  • InSite Vision Incorporated - Dormant Projects
  • InSite Vision Incorporated - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ISV-208
  • InSite Vision Incorporated - Company Statement
  • InSite Vision Incorporated - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • InSite Vision Incorporated, Key Information
  • InSite Vision Incorporated, Key Facts
  • InSite Vision Incorporated - Pipeline by Indication, 2015
  • InSite Vision Incorporated - Pipeline by Stage of Development, 2015
  • InSite Vision Incorporated - Monotherapy Products in Pipeline, 2015
  • InSite Vision Incorporated - Combination Treatment Modalities in Pipeline, 2015
  • InSite Vision Incorporated - Phase III, 2015
  • InSite Vision Incorporated - Phase II, 2015
  • InSite Vision Incorporated - Preclinical, 2015
  • InSite Vision Incorporated - Discovery, 2015
  • InSite Vision Incorporated - Pipeline by Target, 2015
  • InSite Vision Incorporated - Pipeline by Route of Administration, 2015
  • InSite Vision Incorporated - Pipeline by Molecule Type, 2015
  • InSite Vision Incorporated - Pipeline Products by Mechanism of Action, 2015
  • InSite Vision Incorporated - Recent Pipeline Updates, 2015
  • InSite Vision Incorporated - Dormant Developmental Projects,2015
  • InSite Vision Incorporated - Discontinued Pipeline Products, 2015
  • InSite Vision Incorporated, Subsidiaries

List of Figures

  • InSite Vision Incorporated - Pipeline by Top 10 Indication, 2015
  • InSite Vision Incorporated - Pipeline by Stage of Development, 2015
  • InSite Vision Incorporated - Monotherapy Products in Pipeline, 2015
  • InSite Vision Incorporated - Pipeline by Top 10 Target, 2015
  • InSite Vision Incorporated - Pipeline by Top 10 Route of Administration, 2015 1
  • InSite Vision Incorporated - Pipeline by Top 10 Molecule Type, 2015
  • InSite Vision Incorporated - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top